The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
Book your consultation at injectco.com/premium-peptide-therapy/ or call (817) 533-7676
In this blog post, we will delve into the mechanisms behind how Dr
The public and online health retailers are starting to use peptides as a catchall term for any chemical taken for well-being, energy, exercise recovery, and more, says Luke Turnock, a criminologist who studies how people use enhancement drugs at the University of Lincoln in England
However, the key factor is supervision